Sikkerhedsprofilen for panitumumab hos patienter, hvis tumor udtrykker KRAS- vildtypen (n = 123), stemte generelt overens med den overordnede analyse af mCRC- monoterapi, der er beskrevet i ovenstående.
The safety profile of panitumumab in patients whose tumour express KRAS wild-type (n = 123) was generally consistent with overall mCRC monotherapy set described above.